DK0832094T3 - Aminosterolforbindelser, som er nyttige som inhibitorer for natrium/proton-omskifteren (NHE), farmaceutiske fremgangsmåder og sammensætninger, som anvender sådanne inhibitorer, og fremgangsmåder til vurdering af den NHE-inhiberende effektivitet af for.. - Google Patents

Aminosterolforbindelser, som er nyttige som inhibitorer for natrium/proton-omskifteren (NHE), farmaceutiske fremgangsmåder og sammensætninger, som anvender sådanne inhibitorer, og fremgangsmåder til vurdering af den NHE-inhiberende effektivitet af for..

Info

Publication number: DK0832094T3
Authority: DK; Denmark
Prior art keywords: inhibitors; nhe; methods; sodium; useful
Prior art date: 1995-06-07

Application number

DK96922490T

Other languages

Danish (da)

English (en)

Inventor

Michael Zasloff

Ann Shinnar

William A Kinney

Jon Williams

Meena N Rao

Mark Anderson

Michael Mclane

Steven Jones

Original Assignee

Genaera Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-07

Publication date

2004-05-17

1995-06-07 Priority claimed from US08/475,572 external-priority patent/US5840936A/en

1995-06-07 Priority claimed from US08/483,057 external-priority patent/US5795885A/en

1995-06-07 Priority claimed from US08/479,457 external-priority patent/US5763430A/en

1995-06-07 Priority claimed from US08/483,059 external-priority patent/US5840740A/en

1995-06-07 Priority claimed from US08/476,855 external-priority patent/US5874597A/en

1995-06-07 Priority claimed from US08/487,443 external-priority patent/US5847172A/en

1995-06-07 Priority claimed from US08/479,455 external-priority patent/US5994336A/en

1996-06-07 Application filed by Genaera Corp filed Critical Genaera Corp

2004-05-17 Application granted granted Critical

2004-05-17 Publication of DK0832094T3 publication Critical patent/DK0832094T3/da

Links

150000001875 compounds Chemical class 0.000 title abstract 7
239000003112 inhibitor Substances 0.000 title abstract 5
238000000034 method Methods 0.000 title abstract 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title abstract 2
229910052708 sodium Inorganic materials 0.000 title abstract 2
239000011734 sodium Substances 0.000 title abstract 2
230000002401 inhibitory effect Effects 0.000 title 1
239000000203 mixture Substances 0.000 title 1
238000012216 screening Methods 0.000 abstract 1
238000001228 spectrum Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Hematology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Pathology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Virology (AREA)

DK96922490T 1995-06-07 1996-06-07 Aminosterolforbindelser, som er nyttige som inhibitorer for natrium/proton-omskifteren (NHE), farmaceutiske fremgangsmåder og sammensætninger, som anvender sådanne inhibitorer, og fremgangsmåder til vurdering af den NHE-inhiberende effektivitet af for.. DK0832094T3 (da)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US08/475,572 US5840936A (en)	1995-06-07	1995-06-07	Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US08/483,057 US5795885A (en)	1995-06-07	1995-06-07	Method of inhibiting profileration of cells by administering an aminosterol compound
US08/479,457 US5763430A (en)	1995-06-07	1995-06-07	Method of treating a viral infection by administering a steroid compound
US08/483,059 US5840740A (en)	1995-06-07	1995-06-07	Aminosterol compounds and a method of treating infection using the aminosterol compounds
US08/476,855 US5874597A (en)	1995-06-07	1995-06-07	Certain aminosterol compounds and pharmaceutical compositions including these compounds
US08/487,443 US5847172A (en)	1995-06-07	1995-06-07	Certain aminosterol compounds and pharmaceutical compositions including these compounds
US08/479,455 US5994336A (en)	1995-06-07	1995-06-07	Method of inhibiting proliferation of cells by administering an aminosterol compound

Publications (1)

Publication Number	Publication Date
DK0832094T3 true DK0832094T3 (da)	2004-05-17

Family

ID=27569803

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96922490T DK0832094T3 (da)	1995-06-07	1996-06-07	Aminosterolforbindelser, som er nyttige som inhibitorer for natrium/proton-omskifteren (NHE), farmaceutiske fremgangsmåder og sammensætninger, som anvender sådanne inhibitorer, og fremgangsmåder til vurdering af den NHE-inhiberende effektivitet af for..

Country Status (10)

Country	Link
EP (2)	EP0832094B1 (fr)
JP (2)	JP4104164B2 (fr)
AT (1)	ATE259375T1 (fr)
AU (1)	AU723663C (fr)
CA (1)	CA2223910C (fr)
DE (1)	DE69631527T2 (fr)
DK (1)	DK0832094T3 (fr)
ES (1)	ES2216049T3 (fr)
PT (1)	PT832094E (fr)
WO (1)	WO1996040728A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5856535A (en) *	1994-08-18	1999-01-05	Magainin Pharmaceuticals, Inc.	Aminosterol ester compounds
US6143738A (en) *	1995-06-07	2000-11-07	Magainin Pharmaceuticals, Inc.	Therapeutic uses for an aminosterol compound
US5792635A (en) *	1995-06-07	1998-08-11	Magainin Pharmaceuticals, Inc.	Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
PT910382E (pt) *	1996-04-26	2003-10-31	Genaera Corp	Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
US6596712B2 (en)	1996-04-26	2003-07-22	Genaera Corporation	Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US7410959B1 (en)	2000-07-13	2008-08-12	Genaera Corporation	Therapeutic uses for aminosterol compounds
WO1997044044A1 (fr) *	1996-05-17	1997-11-27	Magainin Pharmaceuticals Inc.	Utilisations therapeutiques d'un compose d'aminosterol
AU5194998A (en) *	1996-11-01	1998-05-29	Magainin Pharmaceuticals, Inc.	Certain aminosterol compounds and uses therefor
US6262283B1 (en)	1996-12-06	2001-07-17	Magainin Pharmaceuticals Inc.	Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
DE19737463A1 (de) *	1997-08-28	1999-03-04	Hoechst Marion Roussel De Gmbh	Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
DK1274718T3 (da)	2000-04-12	2007-02-12	Genaera Corp	En fremgangsmåde til forberedelse af 7.alpha.-hydroxy 3-aminosubstituerede steroler vee en ubeskyttet 7.alpha.-hydroxy gruppe
WO2006119211A2 (fr) *	2005-05-02	2006-11-09	Genaera Corporation	Procedes et compositions pour traiter des troubles oculaires
MX2008013592A (es) *	2006-04-21	2009-03-06	Genaera Corp	Induccion de perdida de peso e inhibicion selectiva de la proteina tirosina fosfatasa 1b.
WO2009032321A2 (fr) *	2007-09-06	2009-03-12	Genaera Corporation	Procédé de traitement du diabète
DK2271327T3 (en) *	2008-05-09	2015-07-13	Merck Patent Gmbh	Pharmaceutical composition comprising rhymeporide for the treatment of diseases associated with beta-cell dysfunction
WO2013041519A1 (fr)	2011-09-19	2013-03-28	ETH Zürich, ETH Transfer	Modulateurs de ror gamma
MX367255B (es) *	2012-04-20	2019-08-12	Ohr Pharmaceutical Inc	Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b).
US11524015B2 (en)	2013-03-15	2022-12-13	Brigham Young University	Methods for treating inflammation, autoimmune disorders and pain
WO2014151411A1 (fr)	2013-03-15	2014-09-25	Brigham Young University	Procédés de traitement d'une inflammation, de troubles auto-immuns et de la douleur
EP2781217A1 (fr) *	2013-03-18	2014-09-24	ETH Zurich	Modulateurs de la gamma ROR
US10040817B2 (en)	2013-10-03	2018-08-07	Enterin Laboratories, Inc.	Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US11690855B2 (en)	2013-10-17	2023-07-04	Brigham Young University	Methods for treating lung infections and inflammation
US20150203527A1 (en)	2014-01-23	2015-07-23	Brigham Young University	Cationic steroidal antimicrobials
US10441595B2 (en) *	2014-06-26	2019-10-15	Brigham Young University	Methods for treating fungal infections
FR3033563B1 (fr) *	2015-03-12	2018-04-13	Virbac	Composes analogues de la squalamine utiles comme agents antibacteriens
FR3055801B1 (fr) *	2016-09-15	2020-10-30	Virbac	Derives esters de squalamine pour le traitement des infections
US11083735B2 (en)	2017-09-08	2021-08-10	Enterin, Inc.	Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
WO2020028810A1 (fr) *	2018-08-03	2020-02-06	Enterin Laboratories	Compositions et méthodes pour traiter des troubles de l'axe intestin-cerveau
US11464789B2 (en)	2018-08-03	2022-10-11	Enterin, Inc.	Aminosterol compositions and methods of using the same for treating schizophrenia
US12186328B2 (en)	2019-05-23	2025-01-07	Brigham Young University	Use of CSA compounds to stimulate stem cells and hair growth
US12503485B2 (en)	2019-08-02	2025-12-23	Enterin, Inc.	Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same
WO2021025974A1 (fr) *	2019-08-02	2021-02-11	Enterin, Inc.	Dérivés de squalamine humaine, compositions associées les comprenant, et procédés d'utilisation correspondants
CN112782300B (zh) *	2020-12-25	2022-04-12	山东省食品药品检验研究院	一种胆烷酸的同分异构体及其检测方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5192756A (en) *	1992-03-18	1993-03-09	The Children's Hospital Of Pennsylvania	Aminosterol antibiotic
AU6392894A (en) *	1993-02-26	1994-09-14	Magainin Pharmaceuticals, Inc.	Chemical synthesis of squalamine
WO1994020520A1 (fr) *	1993-03-10	1994-09-15	Magainin Pharmaceuticals Inc.	Derives steroidiens, compositions pharmaceutiques contenant ces derives steroidiens et utilisation de ces derniers comme antibiotiques ou desinfectants

1996
- 1996-06-07 AU AU63349/96A patent/AU723663C/en not_active Ceased
- 1996-06-07 EP EP96922490A patent/EP0832094B1/fr not_active Expired - Lifetime
- 1996-06-07 CA CA002223910A patent/CA2223910C/fr not_active Expired - Lifetime
- 1996-06-07 JP JP50230797A patent/JP4104164B2/ja not_active Expired - Lifetime
- 1996-06-07 AT AT96922490T patent/ATE259375T1/de not_active IP Right Cessation
- 1996-06-07 ES ES96922490T patent/ES2216049T3/es not_active Expired - Lifetime
- 1996-06-07 PT PT96922490T patent/PT832094E/pt unknown
- 1996-06-07 DE DE69631527T patent/DE69631527T2/de not_active Expired - Lifetime
- 1996-06-07 DK DK96922490T patent/DK0832094T3/da active
- 1996-06-07 EP EP04002943A patent/EP1420027A3/fr not_active Withdrawn
- 1996-06-07 WO PCT/US1996/010508 patent/WO1996040728A2/fr not_active Ceased
2007
- 2007-08-29 JP JP2007223309A patent/JP2007314577A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
ES2216049T3 (es)	2004-10-16
AU723663B2 (en)	2000-08-31
EP0832094B1 (fr)	2004-02-11
EP1420027A3 (fr)	2012-01-04
JP2002515019A (ja)	2002-05-21
PT832094E (pt)	2004-06-30
AU6334996A (en)	1996-12-30
AU723663C (en)	2001-11-01
DE69631527T2 (de)	2004-09-23
JP4104164B2 (ja)	2008-06-18
CA2223910A1 (fr)	1996-12-19
EP1420027A2 (fr)	2004-05-19
WO1996040728A2 (fr)	1996-12-19
ATE259375T1 (de)	2004-02-15
DE69631527D1 (de)	2004-03-18
EP0832094A2 (fr)	1998-04-01
WO1996040728A3 (fr)	1997-03-27
JP2007314577A (ja)	2007-12-06
CA2223910C (fr)	2008-09-16

Publication	Publication Date	Title
DK0832094T3 (da)	2004-05-17	Aminosterolforbindelser, som er nyttige som inhibitorer for natrium/proton-omskifteren (NHE), farmaceutiske fremgangsmåder og sammensætninger, som anvender sådanne inhibitorer, og fremgangsmåder til vurdering af den NHE-inhiberende effektivitet af for..
ZA964819B (en)	1998-02-09	Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds.
ES2167905T3 (es)	2002-05-16	Composiciones herbicidas.
NO992821L (no)	1999-06-11	Ketobenzamider som calpain-inhibitorer
NO982802L (no)	1998-08-20	Nye 5-amino-3-cyano-4-etylsulfinyl-1-fenyl-pyrazol-forbindelser og deres anvendelse som pesticider
DK0785770T3 (da)	2000-11-20	Sammensætninger til bekæmpelse af hæmorroider og fremgangsmåde til anvendelse deraf
PT946100E (pt)	2003-11-28	Composicoes herbicidas contendo n-¬(4,6-dimetoxipirimidin-2-il)aminocarbonil\|-5-metilsulfonamidometil-2-alcoxicarbonilbenzenossulfonamidas
DE69531403D1 (de)	2003-09-04	Allosterische modulatoren des nmda-rezeptors
ES2193252T3 (es)	2003-11-01	Quinolonas y su uso terapeutico.
NO961664D0 (no)	1996-04-25	Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som anti-diabetiske midler
FI932695A7 (fi)	1993-12-13	Angiotensiini I kymaasi(e)n inhibiittoreita, mukaanlukien ihmisen sydänkymaasin
ZA964818B (en)	1997-12-08	Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds.
BR9607560A (pt)	1998-12-15	Composições cométicas anidras contendo agentes dermatologicamente ativo
ATE168682T1 (de)	1998-08-15	Herbizide substituierte 1-phenyl-oder 1-pyridinyl-benzotriazole
MX9700807A (es)	1997-05-31	Derivados de 3-azabiciclo (3.2.0)heptano n-sustituidos utiles como neurolepticos.
DK0658585T3 (da)	2000-11-27	Amidinophenylalaninderivater, fremgangsmåde til deres fremstilling, deres anvendelse og midler indeholdende disse som antik
DK0758312T3 (da)	2000-05-01	Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
NO943765L (no)	1995-04-10	Aryloksybenzen-herbicidmidler
BR9607226A (pt)	1998-07-07	Composições herbicidas mistas
NO995676D0 (no)	1999-11-19	Isoftalamid derivat som gul polymorf
ITMI930250A1 (it)	1994-08-11	Perno-moncone amovibile per impianti endossei
NO20010626D0 (no)	2001-02-06	N-substituerte azabicykloheptanderivater, deres fremstilling og anvendelse
DE69304011D1 (de)	1996-09-19	N-Substituierte Carbonyloxyalkylpyrrol enthaltende insekticide, acarizide und molluskizide Mittel
DK1105388T3 (da)	2003-08-18	N-substituerede azabicycloheptan-derivater, fremstilling og anvendelse heraf
DK0877730T3 (da)	2002-12-30	Arylacrylforbindelser til anvendelse som fungicider